MedPath

Clinical Performance of Withings Move ECG Software for Atrial Fibrillation Detection

Conditions
Atrial Fibrillation
Interventions
Diagnostic Test: ECG measurement
Registration Number
NCT04493749
Lead Sponsor
Withings
Brief Summary

Withings Move ECG watch is designed to record ECG and detect automatically atrial fibrillation. The aim of this study is to validate the performance of Move ECG watch to detect atrial fibrillation compared to a reference 12-lead ECG.

Detailed Description

Patients with atrial fibrillation are included in hospitals. On each patient, ECG with Move ECG and the reference 12-lead ECG are recorded simultaneously. Both records are then reviewed by independent cardiologists to assess

1. The presence or absence of atrial fibrillation

2. if waveforms of ECG recorded with Move ECG compared with the reference.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
234
Inclusion Criteria
  • male or female who are 18 years or older
  • Subject who signed the written informed consent form
Exclusion Criteria
  • Vulnerable subject with regard to regulations
  • Pregnant, parturient or breastfeeding woman,
  • Subject who is deprived of liberty by judicial, medical or administrative decision,
  • Underage subject,
  • Legally protected subject, or subject who is unable to sign the written informed consent form,
  • Subject who is not beneficiary or not affiliated to a social security scheme,
  • Subject within several of the above categories,
  • Subject who refused to participate in the study,
  • Subject in physical incapacity to wear a wrist-worn watch
  • Subject with electrical stimulation by pacemaker

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
atrial fibrillation (AF)ECG measurementPatients diagnosed with AF during reference ECG
sinus rhythm (SR)ECG measurementPatients diagnosed with SR during reference ECG
Primary Outcome Measures
NameTimeMethod
Sensitivity and Specificity of the automatic classification in AF by Move ECG single-lead ECG against reference 12-lead ECG1 year

sensitivity from the 2x2 confusion matrix AF vs 'non-AF'

Secondary Outcome Measures
NameTimeMethod
Comparability of ECG waveforms from single strip of Move ECG vs Lead-1 of reference 12-lead ECG1 year

Visibility and polarity of P waves, QRS complex and T waves + length of QT interval, QRS width and PR interval + heart rate

Safety of use of Move ECG1 year

Frequency of adverse event appearance

Trial Locations

Locations (3)

Institut Cœur Paris Centre Turin

🇫🇷

Paris, Ile-de-France, France

Centre Cardiologique du Nord

🇫🇷

Saint-Denis, Ile-de-France, France

Hopital Europeen Georges Pompidou

🇫🇷

Paris, Ile-de-France, France

© Copyright 2025. All Rights Reserved by MedPath